By Colin Kellaher The Food and Drug Administration has officially pulled its authorization of the anticancer drug Pepaxto from Swedish biotech Oncopeptides..
June 19, 2023 Oncopeptides today announced its first named patient sales of its flagship drug Pepaxti in Greece. The sales were made possible through. | June 19, 2023
Oncopeptides AB , a biotech company focused on difficult-to-treat cancers, today announced that Holger Lembrer, Chief Financial Officer has decided to leave Oncopeptides to pursue a new role in. | June 15, 2023
The shareholders in Oncopeptides AB , reg. no. 556596-6438, with registered office in the municipality of Stockholm, are hereby given notice to attend the Annual General Meeting to be held at. | April 24, 2023
STOCKHOLM, Jan. 18, 2023 /PRNewswire/ Oncopeptides AB (publ.) (NASDAQ Stockholm: ONCO), a biotech company focused on commercialization, research, and development of therapies for difficult-to-treat